Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 09/24 07:28:02 am
123.675 EUR   -0.82%
09/21MERCK KGAA : Receives a Sell rating from Goldman Sachs
MD
09/21MERCK : Darmstadt, Germany, Opens State-of-the-art Research Center for Electronic Applications in Darmstadt
PU
09/18MERCK : Agenda
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Merck KGaA Backs 2019 View; Sees Profitable Growth Over Next Years

share with twitter share with LinkedIn share with facebook
09/11/2019 | 02:02am EDT

By Max Bernhard

Germany's Merck KGaA (MRK.XE) on Wednesday backed its guidance for the year and said that it also expects profitable growth in the years to come.

"For 2019, we continue to assume that the group will increase all its key figures: sales, EBITDA pre and EPS pre. We also have our sights firmly set on profitable growth for 2020 and beyond," Chief Executive Stefan Oschmann said at the pharmaceutical company's capital markets day.

Merck also said that by 2022, it targets additional annual sales of around 2 billion euros with new medicines. Its Mavenclad and Bavencio drugs are expected to contribute significantly to this, it added.

The company said it aims for maintained above-market growth in its life-science business and for its performance materials unit to resume growth as of 2020.

Write to Max Bernhard at max.bernhard@dowjones.com; @mxbernhard

Stocks mentioned in the article
ChangeLast1st jan.
JUST GROUP PLC -0.22% 44.67 Delayed Quote.-43.32%
MAX CO., LTD. -1.51% 1567 End-of-day quote.-28.58%
MERCK & CO., INC. -0.37% 82.63 Delayed Quote.-9.15%
MERCK KGAA -0.76% 123.7 Delayed Quote.18.37%
WILL GROUP, INC. -6.31% 876 End-of-day quote.-30.03%
share with twitter share with LinkedIn share with facebook
All news about MERCK KGAA
09/21MERCK KGAA : Receives a Sell rating from Goldman Sachs
MD
09/21MERCK : Darmstadt, Germany, Opens State-of-the-art Research Center for Electroni..
PU
09/18MERCK : Agenda
PU
09/18MERCK KGAA : Buy rating from Independant Research
MD
09/18MERCK : BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The ..
PU
09/17MERCK KGAA : JP Morgan gives a Neutral rating
MD
09/17MERCK KGAA : Credit Suisse gives a Buy rating
MD
09/16MERCK KGAA : Bernstein remains Neutral
MD
09/16MERCK : says it has overcome production shortages in vaccine materials
RE
09/16MERCK KGAA : JP Morgan sticks Neutral
MD
More news
Financials
Sales 2020 17 300 M 20 164 M 20 164 M
Net income 2020 1 688 M 1 967 M 1 967 M
Net Debt 2020 10 709 M 12 482 M 12 482 M
P/E ratio 2020 31,5x
Yield 2020 1,07%
Capitalization 54 217 M 63 337 M 63 192 M
EV / Sales 2020 3,75x
EV / Sales 2021 3,47x
Nbr of Employees 57 523
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 122,76 €
Last Close Price 124,70 €
Spread / Highest target 20,3%
Spread / Average Target -1,56%
Spread / Lowest Target -26,2%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA18.37%63 337
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD115.07%20 935
KYOWA KIRIN CO., LTD.11.74%14 664
BETTA PHARMACEUTICALS CO., LTD.76.39%6 854
YUHAN CORPORATION37.21%3 477
LUYE PHARMA GROUP LTD.-21.40%1 924